The introduction of MET-097i is setting a new benchmark in the realm of metabolic therapies, especially for patients dealing with obesity and type 2 diabetes. Developed by Metsera, MET-097i is a next-generation GLP-1 receptor agonist, notable for its fully biased, ultra-long-acting design that provides prolonged therapeutic benefits and improved signaling precision. This innovative advancement...
English 
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt